drugset / Trial / NCT01379521

Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC

NCT01379521 ↗

Phase 2 Terminated 65 enrolled Novartis Pharmaceuticals
RandomizedSingle-groupQuadruple-blindTreatment

Summary

This study will evaluate the role of everolimus in combination with local Transcatheter Arterial Chemoembolization (TACE) procedure in patients with localized unresectable Hepatocellular Carcinoma (HCC).

Timeline

Start
2011-06
Primary completion
2015-06
Completion
2015-06

Outcome

Outcome not reported

Stopped (Enrollment): “The study was terminated due to low enrollment. This resulted in the study being underpowered and inconclusive.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule 7.5 mg Oral